Log in

Relevant bibliographies by topics / Sacubitril / Journal articles

To see the other types of publications on this topic, follow the link: Sacubitril.

Journal articles on the topic 'Sacubitril'

Author: Grafiati

Published: 11 September 2021

Last updated: 30 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Sacubitril.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ryazanov, Alexey S., Evgenia V. Shikh, Konstantin I. Kapitonov, Mariya V. Makarovskaya, and Alexey A. Kudryavtsev. "The Effect of Angiotensin Receptor Inhibitors and Neprilysin on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction." Annals of the Russian academy of medical sciences 76, no. 3 (2021): 298–306. http://dx.doi.org/10.15690/vramn1526.

Full text

Abstract:

Background. Compared with enalapril, sacubitril/valsartan reduces mortality from cardiovascular diseases and the number of hospitalizations for heart failure in patients with heart failure and reduced ejection fraction (HFrEF). These benefits may be related to effects on hemodynamics and cardiac remodeling. The aim of the study is to determine the effect of sacubitril/valsartan on aortic stiffness and cardiac remodeling compared with enalapril in HFrEF. Materials and methods. In this long-term outpatient study, 100 patients with HFrEF received sacubitril/valsartan or enalapril. The primary end

APA, Harvard, Vancouver, ISO, and other styles

2

Zhang, Ting, Jin-lian Cai, and Jie Yu. "Sacubitril/valsartan-induced liver injury: A case report and literature review." Medicine 102, no. 32 (2023): e34732. http://dx.doi.org/10.1097/md.0000000000034732.

Full text

Abstract:

Rationale: Sacubitril/valsartan (Entresto) is the first drug approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adult patients. There have been no reports of hepatotoxicity secondary to sacubitril/valsartan administration. Here, we report the first case of severe liver injury caused by sacubitril/valsartan. Patient concerns: A 90-year-old female patient taking sacubitril/valsartan was admitted due to chronic heart failure. Subsequently, the patient developed serious liver injury with increased hepatic transaminases. Diagnosis: Drug-induced liver i

APA, Harvard, Vancouver, ISO, and other styles

3

Alves-Lopes, Rhéure, Augusto C. Montezano, Karla B. Neves, et al. "Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension." Hypertension 78, no. 3 (2021): 604–16. http://dx.doi.org/10.1161/hypertensionaha.121.17041.

Full text

Abstract:

Combined inhibition of NEP (neutral endopeptidase) and ACE (angiotensin-converting enzyme), without unwanted effects, remains an attractive therapeutic strategy in cardiovascular medicine. Omapatrilat, a dual NEP inhibitor–ACE inhibitor, was a promising antihypertensive drug but failed in trials due to angioedema, an effect possibly caused by inhibition of both the N- and C-domains of ACE. Here, we aimed to determine whether lisinopril-tryptophan (lisW-S), a C-domain specific ACE inhibitor that preserves the N-domain catalytic activity, together with sacubitril (NEP inhibitor), differentially

APA, Harvard, Vancouver, ISO, and other styles

4

Rakugi, Hiromi, Kazuomi Kario, Masako Yamaguchi, Takayoshi Sasajima, Hiromi Gotou, and Jack Zhang. "Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study." Hypertension Research 45, no. 5 (2022): 824–33. http://dx.doi.org/10.1038/s41440-021-00819-7.

Full text

Abstract:

AbstractThis phase III study assessed the efficacy and safety of sacubitril/valsartan compared with those of olmesartan in Japanese patients with essential hypertension. Patients (n = 1161, aged ≥20 years) with mild to moderate hypertension (mean sitting systolic blood pressure [msSBP] ≥150 to <180 mmHg) were randomized to receive sacubitril/valsartan 200 mg (n = 387), sacubitril/valsartan 400 mg (n = 385), or olmesartan 20 mg (n = 389) once daily for 8 weeks. The primary assessment was a reduction in msSBP from baseline with sacubitril/valsartan 200 mg vs. olmesartan 20 mg at Week 8. Secon

APA, Harvard, Vancouver, ISO, and other styles

5

Maslov, Mikhail Y., Stephan Foianini, Dita Mayer, Michael V. Orlov, and Mark A. Lovich. "Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure." American Journal of Physiology-Heart and Circulatory Physiology 316, no. 2 (2019): H289—H297. http://dx.doi.org/10.1152/ajpheart.00579.2018.

Full text

Abstract:

Simultaneous neprilysin inhibition (NEPi) and angiotensin receptor blockade (ARB) with sacubitril/valsartan improves cardiac function and exercise tolerance in patients with heart failure. However, it is not known whether these therapeutic benefits are primarily due to NEPi with sacubitril or ARB with valsartan or their combination. Therefore, the aim of the present study was to investigate the potential contribution of sacubitril and valsartan to the benefits of the combination therapy on left ventricular (LV) function and exercise tolerance. Heart failure was induced by volume overload via p

APA, Harvard, Vancouver, ISO, and other styles

6

Chen, Zhulu, Chuan Zhang, Yuxi Zhu, Diansa Gao, Min Mao, and Zhong Zuo. "Sacubitril/valsartan can improve the cardiac function in heart failure patients with a history of cancer: An observational study." Medicine 103, no. 12 (2024): e37613. http://dx.doi.org/10.1097/md.0000000000037613.

Full text

Abstract:

Sacubitril/Valsartan, the combination of angiotensin receptor inhibitor and neprilysin inhibitor, is now becoming the class 1 recommendation for HFrEF. Some studies have shown the positive effect of Sacubitril/Valsartan on HFrEF cancer patients, while there is devoid of evidence about the effect of this drug in aged cancer patients with HFmrEF and HFpEF. By searching the patients with a diagnosis of both cancer and Heart failure (HF) over 65, the patients who had received treatment with Sacubitril/Valsartan were selected as the candidates for Sacubitril/Valsartan group, and the patients who ha

APA, Harvard, Vancouver, ISO, and other styles

7

Badreldin, Hisham A., Nasser Aldosari, Lama Alnashwan, et al. "What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies." Journal of Cardiovascular Development and Disease 9, no. 2 (2022): 54. http://dx.doi.org/10.3390/jcdd9020054.

Full text

Abstract:

Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF study in 2014. Therefore, for patients with HFrEF, worldwide recommendations have been reformed to include sacubitril/valsartan. In addition, sacubitril/valsartan has been investigated in other cardiovascular disease states, such as patients with heart failure and preserved ejection fraction (HFpEF) and following myocardial infarction (M

APA, Harvard, Vancouver, ISO, and other styles

8

Zhang, Wei, Jin Zhang, Jie Yan, et al. "P148 EFFICACY AND SAFETY OF SACUBITRIL/ALLISARTAN FOR THE TREATMENT OF PRIMARY HYPERTENSION: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY." Journal of Hypertension 42, Suppl 3 (2024): e112-e113. http://dx.doi.org/10.1097/01.hjh.0001063464.65046.75.

Full text

Abstract:

Background: This randomized, double-blind, phase 3 study assessed the efficacy and safety of sacubitril/allisartan, an angiotensin receptor neprilysin inhibitor, compared with olmesartan in Chinese patients with mild to moderate hypertension. Methods: Eligible patients aged 18-75 years (n=1197) with mild to moderate hypertension were randomized to receive sacubitril/allisartan 240 mg (n=399), sacubitril/allisartan 480 mg (n=399), or olmesartan 20 mg (n=399) once daily for 12 weeks. Patients who completed the 12-week treatment then received another 12-week extended treatment (n=1084) and 28-wee

APA, Harvard, Vancouver, ISO, and other styles

9

Zhang, Wei, Jin Zhang, Jie Yan, et al. "EFFICACY AND SAFETY OF SACUBITRIL/ALLISARTAN FOR THE TREATMENT OF PRIMARY HYPERTENSION: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY." Journal of Hypertension 42, Suppl 1 (2024): e45. http://dx.doi.org/10.1097/01.hjh.0001019708.19000.e1.

Full text

Abstract:

Objective: This randomized, double-blind, phase 3 study assessed the efficacy and safety of sacubitril/allisartan, an angiotensin receptor neprilysin inhibitor, compared with olmesartan in Chinese patients with mild to moderate hypertension. Design and method: Eligible patients aged 18-75 years (n=1197) with mild to moderate hypertension were randomized to receive sacubitril/allisartan 240 mg (n=399), sacubitril/allisartan 480 mg (n=399), or olmesartan 20 mg (n=399) once daily for 12 weeks. Patients who completed the 12-week treatment then received another 12-week extended treatment (n=1084) a

APA, Harvard, Vancouver, ISO, and other styles

10

Sciatti, Edoardo, Michele Senni, Carlo M. Lombardi, Mauro Gori, and Marco Metra. "Sacubitril/valsartan." Journal of Cardiovascular Medicine 19, no. 9 (2018): 473–79. http://dx.doi.org/10.2459/jcm.0000000000000687.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Sible, Alexandra M., James J. Nawarskas, David Alajajian, and Joe R. Anderson. "Sacubitril/Valsartan." Cardiology in Review 24, no. 1 (2016): 41–47. http://dx.doi.org/10.1097/crd.0000000000000093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Cada, Dennis J., Danial E. Baker, and James Leonard. "Sacubitril/Valsartan." Hospital Pharmacy 50, no. 11 (2015): 1025–36. http://dx.doi.org/10.1310/hpj5011-1025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Docherty, Kieran F., Muthiah Vaduganathan, Scott D. Solomon, and John J. V. McMurray. "Sacubitril/Valsartan." JACC: Heart Failure 8, no. 10 (2020): 800–810. http://dx.doi.org/10.1016/j.jchf.2020.06.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Baliga, Ragavendra R. "Sacubitril/Valsartan." Heart Failure Clinics 14, no. 4 (2018): 479–91. http://dx.doi.org/10.1016/j.hfc.2018.06.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Nikolic, Marina, Nevena Jeremic, Nevena Lazarevic, et al. "Sacubitril/valsartan promotes white adipose tissue browning in rats with metabolic syndrome through activation of mTORC1." BioFactors, January 29, 2024. http://dx.doi.org/10.1002/biof.2040.

Full text

Abstract:

AbstractIn addition to their usual use in the treatment of cardiovascular disease, weak evidence is available for the potential of combined use of neprilysin inhibitor (sacubitril) and AT1 receptor antagonist (valsartan) to promote browning of white adipose tissue (WAT) in rats with metabolic syndrome (MetS). This study involved 32 male Wistar albino rats divided into four groups: CTRL—healthy control rats; ENT—healthy rats treated with sacubitril/valsartan; MS—rats with MetS; MS + ENT—rats with MetS treated with sacubitril/valsartan. After finishing the experimental protocol, different WAT de

APA, Harvard, Vancouver, ISO, and other styles

16

Litwin, Sheldon E., and Cara A. East. "Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure." Frontiers in Cardiovascular Medicine 9 (December 22, 2022). http://dx.doi.org/10.3389/fcvm.2022.1058998.

Full text

Abstract:

Of the various medical therapies for heart failure (HF), sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor that combines sacubitril, a pro-drug that is further metabolized to the neprilysin inhibitor sacubitrilat, and the angiotensin II type 1 receptor blocker valsartan. Inhibition of neprilysin and blockade of the angiotensin II type 1 receptor with sacubitril/valsartan increases vasoactive peptide levels, increasing vasodilation, natriuresis, and diuresis. Left ventricular ejection fraction (LVEF) is widely used to classify HF, to assist with clinical decisio

APA, Harvard, Vancouver, ISO, and other styles

17

"Sacubitril." Reactions Weekly 1858, no. 1 (2021): 348. http://dx.doi.org/10.1007/s40278-021-97066-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Guerra, F., L. Pimpini, M. Flori, et al. "Sacubitril/valsartan reduces atrial fibrillation and supraventricular arrhythmias in patients with HFrEF and remote monitoring: preliminary data from the SAVE THE RHYTHM." European Heart Journal 41, Supplement_2 (2020). http://dx.doi.org/10.1093/ehjci/ehaa946.0926.

Full text

Abstract:

Abstract Background Sacubitril/valsartan, the first combined angiotensin receptor-neprilysin inhibitor, has demonstrated a significant benefit compared to angiotensin inhibitor in decreasing ventricular arrhythmias and appropriate implantable cardioverter defibrillator (ICD) shocks in patients with heart failure with reduced ejection fraction (HFrEF). At present, there is no study which evaluates the effect of sacubitril/valsartan on the supraventricular arrhythmic burden in HFrEF patients with an ICD or cardiac resynchronisation therapy-defibrillator (CRT-D) and remote monitoring. Purpose To

APA, Harvard, Vancouver, ISO, and other styles

19

Frommeyer, G., D. Dimanski, C. Ellermann, J. Wolfes, and L. Eckardt. "Beneficial electrophysiologic effects of sacubitril in different arrhythmia syndromes." European Heart Journal 41, Supplement_2 (2020). http://dx.doi.org/10.1093/ehjci/ehaa946.0327.

Full text

Abstract:

Abstract Background Previous studies report conflicting data regarding anti- or proarrhythmic effects of sacubitril. The aim of the presents study was to assess the impact of sacubitril in different arrhythmia models. Methods and results In 12 isolated rabbit hearts, sacubitril was infused in rising concentrations (3, 5, 10μM) after obtaining baseline data. In 12 further hearts, erythromycin was administered to simulate long QT syndrome-2 (LQT2). Other 12 hearts were perfused with veratridine to mimic long QT syndrome-3 (LQT3). Both LQT groups were treated with sacubitril (5μM). Ventricular vu

APA, Harvard, Vancouver, ISO, and other styles

20

Gray, Elizabeth Alana, Sanket N. Patel, Peter A. Doris, and Tahir Hussain. "Combining Neprilysin Inhibitor With AT2R Agonist Is Superior to Combination With AT1R Blocker in Providing Reno-Protection in Obese Rats." Frontiers in Pharmacology 12 (February 7, 2022). http://dx.doi.org/10.3389/fphar.2021.778953.

Full text

Abstract:

Clinical use of the combination therapy of the neprilysin inhibitor sacubitril and angiotensin II type 1 receptor blocker valsartan is known to be associated with albuminuria. Albuminuria is both a risk factor for and an indicator of kidney injury. Earlier work from our laboratory reported that the agonist of angiotensin II type 2 receptor Compound 21 (C21) prevents proteinuria, albuminuria, and is reno-protective in obese Zucker rats fed high salt diet (HSD). Thus, we hypothesized that sacubitril/C21 combination provides superior reno-protection compared to sacubitril/valsartan. Male obese Zu

APA, Harvard, Vancouver, ISO, and other styles

21

Lin, Wan‐Ying, Yu‐Hsuan Joni Shao, Andy F. Chiang, et al. "Long‐Term Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction and Coexisting End‐Stage Renal Disease." Clinical Pharmacology & Therapeutics, June 16, 2024. http://dx.doi.org/10.1002/cpt.3315.

Full text

Abstract:

Sacubitril/valsartan (Entresto) has proven therapeutic effects in heart failure (HF) patients, but its impact on those with advanced chronic kidney disease (CKD) remains unclear, particularly in HF patients with coexisting end‐stage renal disease (ESRD). This study aims to assess the long‐term survival of patients with heart failure with reduced ejection fraction (HFrEF) and coexisting ESRD treated with sacubitril/valsartan. A retrospective cohort study included 2,860 HFrEF and ESRD patients between January 2008 and December 2020. After propensity score matching, data from a sacubitril/valsart

APA, Harvard, Vancouver, ISO, and other styles

22

Ahmad, Javaria, Ali Sultan, and Paari Dominic. "Abstract 10789: Effect of Sacubitril-Valsartan on Incidence of Atrial Fibrillation: A Meta-Analysis." Circulation 144, Suppl_1 (2021). http://dx.doi.org/10.1161/circ.144.suppl_1.10789.

Full text

Abstract:

Introduction: Sacubitril/valsartan reduces all cause mortality in heart failure (HF) patients compared to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). ACEIs/ARBs have been shown to decrease the incidence of atrial fibrillation (AF). Hypothesis: Sacubitril-Valsartan decreases the incidence of AF compared to ACEis/ARBs. Methods: Clinicaltrials.gov was searched for trials by terms sacubitril/valsartan, entresto, sacubitril, valsartan. Randomized controlled human trials of sacubitril/valsartan reporting AF were included. Data were extracted independent

APA, Harvard, Vancouver, ISO, and other styles

23

Akerman, Caitlin C., and Janna C. Beavers. "Risk Factors for Intolerance of Inpatient Sacubitril/Valsartan Initiation." Journal of Pharmacy Practice, October 3, 2019, 089719001987894. http://dx.doi.org/10.1177/0897190019878948.

Full text

Abstract:

Background: Sacubitril/valsartan has been shown to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, initiation of sacubitril/valsartan has primarily been studied in stable, ambulatory patients with HFrEF. Objective: The objective of this study was to determine risk factors for intolerance to inpatient sacubitril/valsartan initiation. Methods: This was a retrospective, single-center study from August 1, 2015 through April 30, 2018. Patients were at least 18 years old and were newly initiated on sacubitril/valsartan during their hospitalization. Re

APA, Harvard, Vancouver, ISO, and other styles

24

Gan, Jaclyn, Haunnah Rheault, and Yee Weng Wong. "Who ‘nose’, is it the angiotensin receptor neprilysin inhibitor?: a case series of persistent nasal pruritus in heart failure patients receiving sacubitril/valsartan." European Heart Journal - Case Reports 5, no. 12 (2021). http://dx.doi.org/10.1093/ehjcr/ytab506.

Full text

Abstract:

Abstract Background Sacubitril/valsartan is approved for the treatment of chronic heart failure with reduced left ventricular ejection fraction of ≤40% to decrease mortality and morbidity. Nasal pruritus is not a recognized adverse effect in the product information. In this case series, we encountered three patients who presented with nasal pruritus that improved after discontinuation of sacubitril/valsartan. Case summary Three patients aged 58–73 years-old presented with pruritus at the nasal septum post-initiation of sacubitril/valsartan. The pruritus did not subside despite the use of anti-

APA, Harvard, Vancouver, ISO, and other styles

25

Burgdorf, Christof, Janine Brockmöller, Henrieke Strampe, Monika Januszewski, and Bjoern Andrew Remppis. "Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction." Frontiers in Cardiovascular Medicine 8 (October 7, 2021). http://dx.doi.org/10.3389/fcvm.2021.734697.

Full text

Abstract:

Objectives: Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril/Valsartan therapy. As HFpEF patients with pulmonary hypertension display a specifically high mortality and morbidity, we evaluated the effect of Sacubitril/Valsartan in this subgroup of HFpEF patients.Methods: In this retrospective case-series of 18 patients with HFpEF and pulmonary hypertension, right heart catheterisation (RHC) for determination of invasive pulmonary pressure were performed at

APA, Harvard, Vancouver, ISO, and other styles

26

Chen, Fan-Yu, Ann Charis Tan, Chyong-Mei Chen, et al. "The association of vascular access flow with sacubitril/valsartan and left ventricular ejection fraction in hemodialysis patients with heart failure with reduced ejection fraction." Clinical Kidney Journal 18, no. 4 (2025). https://doi.org/10.1093/ckj/sfaf078.

Full text

Abstract:

ABSTRACT Background Sacubitril/valsartan improves heart function in maintenance hemodialysis (HD) patients with heart failure with a reduced ejection fraction of &lt;40% (HFrEF). However, the effect of sacubitril/valsartan on vascular access flow (Qa) in this population is still unclear. Methods Hemodialysis patients with HFrEF were enrolled and divided into sacubitril/valsartan and non-sacubitril/valsartan treatment groups and received echocardiographic and Qa measurements at baseline and after 12 months. We compared the changes in Qa (△Qa) and echocardiographic parameters after 12 months

APA, Harvard, Vancouver, ISO, and other styles

27

Kido, Kazuhiko, Christopher Bianco, Marco Caccamo, Masayuki Hashiguchi, Lyn Yuen Choo, and George Sokos. "Sacubitril/Valsartan Does Not Change the Use and Dose of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction." Journal of Pharmacy Practice, May 16, 2023, 089719002311772. http://dx.doi.org/10.1177/08971900231177202.

Full text

Abstract:

Background There is no standard approach for managing the use or dose of loop diuretics after initiating sacubitril/valsartan. Objective To investigate longitudinal trends in loop diuretic therapy use and doses during the initial 6 months following sacubitril/valsartan initiation. Methods This retrospective cohort study included adult patients who were initiated on sacubitril/valsartan in cardiology clinics. Inclusion criteria were patients diagnosed with heart failure with reduced ejection fraction (ejection fraction ≤40%) and initiated on sacubitril/valsartan in an outpatient setting. We inv

APA, Harvard, Vancouver, ISO, and other styles

28

Chen, Qingsong, Yunlin Chen, Fang Qin, et al. "Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation." Frontiers in Cardiovascular Medicine 9 (May 30, 2022). http://dx.doi.org/10.3389/fcvm.2022.870203.

Full text

Abstract:

BackgroundExisting studies have shown that sacubitril-valsartan ameliorated atrial remodeling in atrial fibrillation (AF) and favored maintenance of sinus rhythm in patients with AF and heart failure. However, the effect of sacubitril-valsartan in patients with persistent AF is yet unknown. We aimed to evaluate the effect of sacubitril-valsartan on restoration and maintenance of sinus rhythm in patients with persistent AF who underwent electrical cardioversion (ECV).MethodConsecutive patients with persistent AF who underwent ECV between 1 January 2016 and 30 September 2020 were investigated in

APA, Harvard, Vancouver, ISO, and other styles

29

Greene, Stephen J., Sujung Choi, Steven J. Lippmann, et al. "Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction." Journal of the American Heart Association 10, no. 16 (2021). http://dx.doi.org/10.1161/jaha.121.021459.

Full text

Abstract:

Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real‐world US practice is unclear. Methods and Results This study included Medicare beneficiaries age ≥65 years who were hospitalized for HFrEF ≤40% in the Get With The Guidelines–Heart Failure registry between October 2015 and December 2018, and eligible for sacubitril/valsartan. Associations between discharge prescription of sacubitril/valsartan and clinical outc

APA, Harvard, Vancouver, ISO, and other styles

30

Mohanty, April F., Emily B. Levitan, Jordan B. King, et al. "Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction." Journal of the American Heart Association 10, no. 20 (2021). http://dx.doi.org/10.1161/jaha.120.020474.

Full text

Abstract:

Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sacubitril/valsartan initiation rate, associated characteristics, and 6‐month follow‐up dosing among veterans with HFrEF who are renin‐angiotensin‐aldosterone system inhibitor (RAASi) naïve. Methods and Results Retrospective cohort study of veterans with HFrEF who are RAASi naïve defined as left ventricular ejection fraction (LVEF) ≤40%; ≥1 in/outpatient

APA, Harvard, Vancouver, ISO, and other styles

31

Ozaki, Aya, Harlan M. Krumholz, Tien Tran, et al. "Abstract 267: National Comparison of Prior Authorization and Utilization of Sacubitril/valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction." Circulation: Cardiovascular Quality and Outcomes 13, Suppl_1 (2020). http://dx.doi.org/10.1161/hcq.13.suppl_1.267.

Full text

Abstract:

Background: Sacubitril/valsartan (Entresto ® ) reduces mortality and heart failure (HF) admissions in NYHA Class II/III HF with reduced ejection fraction (HFrEF). However, uptake in practice has been lower than expected. Prior authorization (PA) is a common barrier that may reduce drug access, which may impact clinical outcomes. Our study characterizes PA requirement burden and use of sacubitril/valsartan by insurance plan type. Methods: We conducted a cross-sectional study using insurance plan information directly from a managed care organization-approved insurance coverage website accessed i

APA, Harvard, Vancouver, ISO, and other styles

32

Hu, Tianyang, Yiting Liu, and Yake Lou. "Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis." Frontiers in Pharmacology 14 (March 2, 2023). http://dx.doi.org/10.3389/fphar.2023.925375.

Full text

Abstract:

Background: The episode of acute decompensated heart failure (ADHF) is the main cause of hospitalization for heart failure (HF). Sacubitril–valsartan has been proven to be effective in reducing the risks of hospitalization for HF in ADHF. When to initiate sacubitril–valsartan in ADHF to make it the most cost-effective in China remains unclear.Methods: A lifetime Markov model with a 1-month cycle length was developed to evaluate the cost-effectiveness of early or late initiation of sacubitril–valsartan versus enalapril in ADHF. Early initiation of sacubitril–valsartan meant that it was initiate

APA, Harvard, Vancouver, ISO, and other styles

33

Guerra, F., P. Marchese, M. Flori, et al. "Sacubitril/valsartan therapy and supraventricular arrhythmias detected through remote monitoring in heart failure patients." EP Europace 23, Supplement_3 (2021). http://dx.doi.org/10.1093/europace/euab116.124.

Full text

Abstract:

Abstract Funding Acknowledgements Type of funding sources: None. Background Sacubitril/valsartan (S/V) has demonstrated a significant benefit in decreasing mortality and morbidity in patients with heart failure with reduced ejection fraction (HFrEF) when compared to angiotensin inhibition. Recent studies demonstrated that the benefits of S/V encompass a positive cardiac remodeling, leading to a reduction of ventricular arrhythmias. The effect of S/V on the supraventricular arrhythmic burden is still unknown. Purpose To evaluate the effect of sacubitril/valsartan on the supraventricular arrhyth

APA, Harvard, Vancouver, ISO, and other styles

34

Guerra, F., P. Marchese, M. Flori, et al. "Sacubitril/valsartan therapy and supraventricular arrhythmias detected through remote monitoring in heart failure patients." May 24, 2021. https://doi.org/10.1093/europace/euab116.124.

Full text

Abstract:

Abstract Funding Acknowledgements Type of funding sources: None. Background Sacubitril/valsartan (S/V) has demonstrated a significant benefit in decreasing mortality and morbidity in patients with heart failure with reduced ejection fraction (HFrEF) when compared to angiotensin inhibition. Recent studies demonstrated that the benefits of S/V encompass a positive cardiac remodeling, leading to a reduction of ventricular arrhythmias. The effect of S/V on the supraventricular arrhythmic burden is still unknown. Purpose To evaluate the effect of sacubitril/valsartan on the supraventricular arrhyth

APA, Harvard, Vancouver, ISO, and other styles

35

"Sacubitril/valsartan." Reactions Weekly 1840, no. 1 (2021): 332. http://dx.doi.org/10.1007/s40278-021-90475-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

"Sacubitril/valsartan." Reactions Weekly 1848, no. 1 (2021): 351. http://dx.doi.org/10.1007/s40278-021-93353-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

"Sacubitril/valsartan." Reactions Weekly 1862, no. 1 (2021): 442. http://dx.doi.org/10.1007/s40278-021-98560-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Sacubitril/valsartan." Reactions Weekly 1908, no. 1 (2022): 499. http://dx.doi.org/10.1007/s40278-022-16227-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Sacubitril/valsartan." Reactions Weekly 1904, no. 1 (2022): 407. http://dx.doi.org/10.1007/s40278-022-14339-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Sacubitril/valsartan." Reactions Weekly 1918, no. 1 (2022): 443. http://dx.doi.org/10.1007/s40278-022-20900-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Sacubitril/valsartan." Reactions Weekly 1914, no. 1 (2022): 393. http://dx.doi.org/10.1007/s40278-022-18979-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Sacubitril/valsartan." Reactions Weekly 1862, no. 1 (2021): 443. http://dx.doi.org/10.1007/s40278-021-98561-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Sacubitril/valsartan." Reactions Weekly 1900, no. 1 (2022): 301. http://dx.doi.org/10.1007/s40278-022-12653-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Sacubitril/valsartan." Reactions Weekly 1875, no. 1 (2021): 305. http://dx.doi.org/10.1007/s40278-021-03221-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Sacubitril/valsartan." Reactions Weekly 1871, no. 1 (2021): 374. http://dx.doi.org/10.1007/s40278-021-01893-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Sacubitril/valsartan." Reactions Weekly 1929, no. 1 (2022): 573. http://dx.doi.org/10.1007/s40278-022-26197-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Sacubitril/valsartan." Reactions Weekly 2039, no. 1 (2024): 504. https://doi.org/10.1007/s40278-024-72941-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Sacubitril/valsartan." Reactions Weekly 2032, no. 1 (2024): 410. http://dx.doi.org/10.1007/s40278-024-70071-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Sacubitril/valsartan." Reactions Weekly 2018, no. 1 (2024): 417. http://dx.doi.org/10.1007/s40278-024-63876-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Sacubitril/valsartan." Reactions Weekly 1691, no. 1 (2018): 244. http://dx.doi.org/10.1007/s40278-018-42499-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!